VATE icon

INNOVATE Corp

5.50 USD
-0.30
5.17%
At close Apr 21, 4:00 PM EDT
1 day
-5.17%
5 days
-14.20%
1 month
-36.19%
3 months
-42.23%
6 months
-10.86%
Year to date
10.00%
1 year
-9.84%
5 years
-99.93%
10 years
-99.98%
 

About: Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.

Employees: 3,161

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

32% more capital invested

Capital invested by funds: $8.91M [Q3] → $11.8M (+$2.86M) [Q4]

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

0.49% less ownership

Funds ownership: 18.45% [Q3] → 17.96% (-0.49%) [Q4]

15% less funds holding

Funds holding: 34 [Q3] → 29 (-5) [Q4]

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for VATE.

Financial journalist opinion

Based on 3 articles about VATE published over the past 30 days

Neutral
GlobeNewsWire
5 days ago
INNOVATE Corp. to Report First Quarter 2025 Results on May 6th
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the first quarter 2025 on Tuesday, May 6, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET.
INNOVATE Corp. to Report First Quarter 2025 Results on May 6th
Neutral
Seeking Alpha
3 weeks ago
INNOVATE Corp. (VATE) Q4 2024 Earnings Call Transcript
INNOVATE Corp. (NYSE:VATE ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Neel Sikka - Investor Relations Paul Voigt - Interim Chief Executive Officer Mike Sena - Chief Financial Officer Conference Call Participants Brian Charles - R.W. Pressprich Operator Good afternoon and welcome to INNOVATE Corp's Fourth Quarter and Full Year 2024 Earnings Conference Call.
INNOVATE Corp. (VATE) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
3 weeks ago
INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results
- Infrastructure: DBM Global fourth quarter revenue of $225.7 million - - Life Sciences: MediBeacon ® Transdermal GFR (“TGFR”) system received FDA approval to assess kidney function - - Spectrum: Broadcasting achieved double-digit revenue growth in the fourth quarter and full year 2024 -
INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results
Neutral
GlobeNewsWire
1 month ago
INNOVATE Corp. to Report Fourth Quarter and Full Year 2024 Results on March 31st
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the fourth quarter and full year 2024 on Monday, March 31, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET.
INNOVATE Corp. to Report Fourth Quarter and Full Year 2024 Results on March 31st
Neutral
GlobeNewsWire
1 month ago
MediBeacon® Transdermal GFR System receives device approval in China
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function. The Clinical Kidney Journal in February published MediBeacon study results on measured GFR (mGFR) using relmapirazin versus estimated GFR (eGFR) for the purpose of classifying patient Chronic Kidney Disease (CKD) stages.
MediBeacon® Transdermal GFR System receives device approval in China
Neutral
GlobeNewsWire
3 months ago
MediBeacon® Transdermal GFR System Receives FDA Approval to Assess Kidney Function
NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) has approved the MediBeacon® TGFR for the assessment of kidney function in patients with normal or impaired renal function.
MediBeacon® Transdermal GFR System Receives FDA Approval to Assess Kidney Function
Neutral
GlobeNewsWire
5 months ago
INNOVATE Corp. Portfolio Company R2 Technologies Announces Another Record-Breaking Quarter and Partnerships with Woodhouse Spas and Top Skincare Brands
NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- R2 Technologies, Inc., the world leader in CryoAesthetics® with its cutting-edge Glacial Skin systems (“R2”), a portfolio company of INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it has achieved several impressive milestones during 2024. The growing momentum of the brand coupled with recent key partnerships has positioned the company for substantial growth across the aesthetics and wellness sectors.
INNOVATE Corp. Portfolio Company R2 Technologies Announces Another Record-Breaking Quarter and Partnerships with Woodhouse Spas and Top Skincare Brands
Neutral
Seeking Alpha
5 months ago
INNOVATE Corp. (VATE) Q3 2024 Earnings Call Transcript
INNOVATE Corp. (VATE) Q3 2024 Earnings Call Transcript
INNOVATE Corp. (VATE) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
5 months ago
INNOVATE Corp. Announces Third Quarter 2024 Results
- Infrastructure: DBM Global third quarter revenue of $232.8 million - - Life Sciences: R2 reports record worldwide system unit sales growth in the third quarter - - Spectrum: Broadcasting's delivered another quarter of strong growth driven by network launches -
INNOVATE Corp. Announces Third Quarter 2024 Results
Neutral
GlobeNewsWire
6 months ago
INNOVATE Corp. to Report Third Quarter 2024 Results on November 6th
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET.
INNOVATE Corp. to Report Third Quarter 2024 Results on November 6th
Charts implemented using Lightweight Charts™